Here are the 10-K annual reports from Tharimmune, Inc. (THAR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow THAR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full THAR filings page.
Canton Strategic Holdings, Inc. is undergoing a major shift from a traditional biotechnology business to a Canton Coin (CC)–focused digital asset treasury and Canton Network participation strategy. The company now prioritizes acquiring, holding and deploying CC, including validator operations and token management.
It still runs clinical-stage biotech programs such as GV104, a buccal nalmefene film for opioid exposure being advanced via the 505(b)(2) pathway, and GV023, an oral infliximab program licensed from Intract. Recent financings include a $545 million November 2025 PIPE and a $54.9 million January 2026 underwritten offering, plus an ATM program allowing up to $300 million of additional stock sales. Management and board changes in late 2025 and early 2026 align leadership with the new CC-centric strategy, which carries significant regulatory, market, custody and volatility risks that could materially affect results and the stock price.